Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance

References

• Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–327.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe d‘Etude des lymphomes de l‘Adulte. J Clin Oncol. 1997;15(3):1110–1117.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [NCCN]. B-cell lymphomas (version 5.2021). 2021. [accessed December 1, 2021]. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191(3):363–381.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Follicular lymphoma: watch and wait is watch and worry. Lancet Oncol. 2014;15(4):368–369.
   PubMed Web of Science ®Google Scholar
• LeBlanc T, Kamal A, Abernethy A. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? Lancet Oncol. 2014;15(7):e251–e252.
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin’s lymphoma. Oncology (Williston Park). 1998;12(5):697–714; discussion 714, 717, 721.
   PubMed Web of Science ®Google Scholar
• Frey S, Blankart CR, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. Pharmacoeconomics. 2016;34(5):479–498.
   PubMed Web of Science ®Google Scholar
• Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma. 2010;51(4):628–640.
   PubMed Web of Science ®Google Scholar
• Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in The Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015;24(12):2895–2906.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139(2):255–264.
   PubMed Web of Science ®Google Scholar
• van den Broek EC, Oerlemans S, Nijziel MR, et al. Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in The Netherlands. Ann Hematol. 2015;94(1):45–56.
   PubMed Web of Science ®Google Scholar
• Mols F, Aaronson NK, Vingerhoets AJ, et al. Quality of life among long-term non-Hodgkin lymphoma survivors. Cancer. 2007;109(8):1659–1667.
   PubMed Web of Science ®Google Scholar
• Hlubocky FJ, Webster K, Cashy J, et al. The development and validation of a measure of health-related quality of life for non-Hodgkin’s lymphoma: the functional assessment of cancer therapy—lymphoma (FACT-Lym). Lymphoma. 2013;2013:1–9.
   Google Scholar
• Yost KJ, Thompson CA, Eton DT, et al. The functional assessment of cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54(2):290–297.
   PubMed Web of Science ®Google Scholar
• Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences. Eval Health Prof. 2005;28(2):172–191.
   PubMed Web of Science ®Google Scholar
• Yost K, Cella D, Chawla A, et al. Minimally important differences were estimated for the functional assessment of cancer therapy–colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol. 2005;58(12):1241–1251.
   PubMed Web of Science ®Google Scholar
• Pearman T, Yanez B, Peipert J, et al. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer. 2014;120(18):2902–2909.
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Kopp M, et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol. 2004;72(6):381–389.
   PubMed Web of Science ®Google Scholar
• Trevino KM, Martin P, Chen Z, et al. Worsening quality of life in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia patients in active surveillance: a 12-month longitudinal study. Clin Lymph Myeloma Leuk. 2022;22(2):82–88.
   PubMed Web of Science ®Google Scholar
• Lehto U-S, Ojanen M, Kellokumpu-Lehtinen P. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol. 2005;16(5):805–816.
   PubMed Web of Science ®Google Scholar
• Parker PA, Baile WF, Moor C, et al. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psycho Oncol. 2003;12(2):183–193.
   PubMed Web of Science ®Google Scholar
• Staniute M, Brozaitiene J, Bunevicius R. Effects of social support and stressful life events on health-related quality of life in coronary artery disease patients. J Cardiovasc Nurs. 2013;28(1):83–89.
   PubMed Web of Science ®Google Scholar
• Hu F, Niu L, Chen R, et al. The association between social Capital and quality of life among type 2 diabetes patients in Anhui province, China: a cross-sectional study. BMC Public Health. 2015;15(1):786.
   PubMedGoogle Scholar
• von Gruenigen VE, Huang HQ, Gil KM, et al. A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a gynecologic oncology group study. J Pain Symptom Manage. 2010;39(5):839–846.
   PubMed Web of Science ®Google Scholar
• Yoo H, Shin DW, Jeong A, et al. Perceived social support and its impact on depression and health-related quality of life: a comparison between cancer patients and general population. JPN J Clin Oncol. 2017;47(8):728–734.
   PubMed Web of Science ®Google Scholar
• Paunescu AC, Paget J, Bergman CC, et al. Gender disparities in quality of life of french patients one year after the diagnosis of lymphoma: a LYSA study. Hematol Oncol. 2021;39(S2):374–375.
   Google Scholar
• Sztankay M, Giesinger J, Holzner B. Gender differences in quality of life in patients with haematological malignancies. Memo. 2011;4(4):224–226.
   Google Scholar
• Laghousi D, Jafari E, Nikbakht H, et al. Gender differences in health-related quality of life among patients with colorectal cancer. J Gastrointest Oncol. 2019;10(3):453–461.
   PubMed Web of Science ®Google Scholar
• Buzaglo JS, Miller MF, Zaleta AK, et al. Chronic lymphocytic leukemia patient reported outcomes and quality of life: findings from the cancer experience registry. Blood. 2017;130(1):2122–2122.
   Google Scholar
• Oerlemans S, Issa DE, van den Broek EC, et al. Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry. Eur J Haematol. 2014;93(3):229–238.
   PubMed Web of Science ®Google Scholar
• Youron P, Singh C, Jindal N, et al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire. Eur J Haematol. 2020;105(6):755–762.
   PubMed Web of Science ®Google Scholar
• Levin TT, Li Y, Riskind J, et al. Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort. General Hospital Psychiatry. 2007;29(3):251–256.
   PubMed Web of Science ®Google Scholar
• Ernst J, Hinz A, Niederwieser D, et al. Dyadic coping of patients with hematologic malignancies and their partners and its relation to quality of life – a longitudinal study. Leuk Lymphoma. 2017;58(3):655–665.
   PubMed Web of Science ®Google Scholar
• Basch E, Barbera L, Kerrigan CL, et al. Implementation of patient-reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book. 2018;38:122–134.
   PubMedGoogle Scholar
• Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA. 2008;105(24):8369–8374.
   PubMed Web of Science ®Google Scholar
• Parker PA, Kim J, Latini DM. Active surveillance and patient support intervention. In: John W. Davis, editors. Robot-assisted radical prostatectomy. Berlin: Springer; 2016. P. 309–315.
   Google Scholar
• Ver Hoeve ES, Ali-Akbarian L, Price SN, et al. Patient-reported financial toxicity, quality of life, and health behaviors in insured U.S. cancer survivors. Support Care Cancer. 2021;29(1):349–358.
   PubMed Web of Science ®Google Scholar
• Xu RH, Wong EL-y, Su Y, et al. Quantifying the effect of financial burden on Health-Related quality of life among patients with Non-Hodgkin’s lymphomas. Cancers. 2020;12(11):3325.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Yost K, Larson MC, et al. Changes in quality of life in indolent Non-Hodgkin lymphoma 3 years after diagnosis. Blood. 2017;130(1):917–917.
   Google Scholar
• Riba MB, Donovan KA, Ahmed K, et al. NCCN clinical practice guidelines in oncology: distress management. Version 2.2022. Plymouth Meeting, Pennsylvania: National Comprehensive Cancer Network 2022.
   Google Scholar